Onkológia 6/2013
Future of treatment of multiple myeloma
The last decade has seen significant advances in our understanding of the biology of multiple myeloma (MM) and our approaches to its treatment. As a result of these advances, the median survival of patients has increased and we can now achieve a cure in at least some patients. Following the success of thalidomide, lenalidomide, and bortezomib in multiple myeloma, a number of novel agents are currently under investigation ( carfilzomib, pomalidomide, monoclonal antibody, HDAC inhibitors ).These targeted therapies may enable personalization of therapy for individuals with myeloma in the future.
Keywords: multiple myeloma, pomalidomide, carfilzomib, HDAC inhibitors, elotuzumab, perifosine, personalization therapy.
